Open Access

Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro

  • Authors:
    • Li Cheng
    • Yan Zhao
    • Maochun Tang
    • Zhengsheng Luo
    • Xingpeng Wang
  • View Affiliations

  • Published online on: February 28, 2019     https://doi.org/10.3892/ol.2019.10082
  • Pages: 4263-4270
  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer is a deadly disease that is frequently associated with mortality at the time of diagnosis due to rapid metastasis, which makes it unsuitable for operative surgery, and resistant to chemotherapy and radiation therapy. Isochorismatase domain‑containing protein 1 (ISOC1) has putative isochorismatase activity, and is positively regulated by estrogen in human breast cancer. However, its role in pancreatic cancer has yet to be fully elucidated. Analysis from datasets downloaded from The Cancer Genome Atlas and Genotype‑Tissue Expression databases indicated that the ISOC1 mRNA expression level was increased in pancreatic cancer tissues, compared with normal pancreatic tissues. In the present study, it was determined that the human pancreatic cancer cell lines SW 1990, PANC‑1 and AsPC‑1 had increased expression levels of ISOC1 mRNA, compared with human pancreatic ductal epithelial cells. Additionally, two of the pancreatic cancer cell lines, SW 1990 and PANC‑1, transfected with lentivirus‑delivered short hairpin RNA, to knockdown the expression of ISOC1, were established. Cell counting and MTT assays indicated that knockdown of ISOC1 decreased the ability of cell growth and proliferation in pancreatic cancer cells. Furthermore, Annexin V staining and caspase‑3/7 activity assays demonstrated that inhibition of ISOC1 promoted cell apoptosis via elevation of the expression of caspase‑3/7. Furthermore, inhibition of ISOC1 impaired the cell migration and invasive capability of the cells. In conclusion, ISOC1 exerts a role in pancreatic cancer cell growth and apoptosis, and may have a role in pancreatic cancer tumorigenesis.

Introduction

Pancreatic cancer is one of the most lethal cancer types, with a 5-year survival rate of 8% according to American Cancer Society Statistics in 2017 (1). The median overall survival time of patient with pancreatic cancer is only 5.0–7.2 months, according to statistics from France published in 2011 (2). The prognosis for patients with pancreatic cancer is poor due to this cancer type frequently being diagnosed at an advanced stage due to rapid progression, with limited symptoms at early stages meaning surgery is applicable only to a minority of patients (<20%), but also because it is resistant to chemotherapeutic agents and radiation therapy (3). The current first-line chemotherapeutic drug, gemcitabine, for pancreatic cancer treatment remains unsatisfactory (2). Therefore, there is an urgent requirement for novel therapeutic approaches and drug combinations to provide a beneficial treatment for patients with pancreatic cancer.

Isochorismatase domain-containing protein 1 (ISOC1) may have putative isochorismatase activity, catalyzing the conversion of isochorismate into 2,3-dihydroxy-2,3-dihydrobenzoate and pyruvate via hydrolysis (4). Aside from its putative isochorismatase activity, the precise function of ISOC1 in human pancreatic cancer has not been fully elucidated. A number of recently published papers, using high-throughput techniques, including genetic sequencing and proteomic mass spectrometry, revealed that ISOC1 was one novel target that is positively regulated by estrogen in breast cancer, negatively regulated by microRNA-130a in neutrophil development and is a new peroxisomal constituent in human liver peroxisomes (58). Collectively, these recent observations indicate that ISOC1 may have important functions in ontogenesis, and that it is worthy of an in-depth investigation.

In the present study, the pancreatic cancer cell lines, SW 1990 and PANC-1, were used to investigate the potential role of ISOC1 in pancreatic cancer. ISOC1 expression was inhibited with short hairpin (sh)ISOC1 in order to determine its effects on cell growth, proliferation, apoptosis, migration and invasion following ISOC1 knockdown. The observations of the present study helped to improve our understanding of the role of ISOC1 in pancreatic cancer.

Materials and methods

Reagents

The Rabbit polyclonal ISOC1 antibody anti-human ISOC1 was purchased from Abcam (#ab118245; Cambridge, UK). Anti-GAPDH (#sc-32233), peroxidase-conjugated antirabbit IgG (#sc-2004) and anti-mouse IgG (#sc-2005) were purchased from Santa-Cruz Biotechnology, Inc. (Dallas, TX, USA). RPMI 1640 medium with L-Gultamine (#11875-093), fetal bovine serum (FBS; #10100-147) and Lipofectamine® 2000 (#11668019) were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Penicillin-streptomycin (#1107440001) and Giemsa staining solution (#32884) were purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany).

Cell lines and cell culture

Human pancreatic carcinoma SW 1990, PANC-1 and AsPC-1 cells and normal pancreatic duct epithelial (HPDE) cells were purchased from American Type Culture Collection (Manassas, VA, USA). These cell lines were maintained at 37°C in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated FBS, penicillin (100 IU/ml) and streptomycin (100 µg/ml).

Construction of ISOC1 knockdown lentivirus

According to the sequence of ISOC1 (NM_016048), shISOC1 and control shRNA (shCtrl) were designed. The sequences are as follows: shISOC1: 5′-CCGGCCATTTGAGTACCAGCATTTACTCGAGTAAATGCTGGTACTCAAATGGTTTTT-3′; and shCtrl: 5′-CCGGCCTTCTCCGAACGTGTCACGTCTCGAGTAAATGCTGGTACTCAAATGGTTTTT-3′. The two shRNAs (100 ng/µl) were inserted into the plasmid GV115 (U6-MCS-CMV-EGFP; Shanghai GeneChem Co., Ltd., Shanghai, China). Recombinant lentiviruses were generated by transfection of 293T cells (Cell Bank of Chinese Academy of Science, Shanghai, China), in a 10 cm dish at 80% confluency, with 20 µg GV115 plasmid and the helper plasmids, including 15 µg Helper 1.0 and 15 µg Helper 2.0 (Shanghai GeneChem Co., Ltd.) using Lipofectamine® 2000. After 48 h of transfection, viral supernatants were collected, centrifuged at 10,000 × g at 4°C to remove cell debris and then filtered through 0.45 µm polyvinylidene fluoride membranes. Lentivirus titer (TU/ml) was measured using HIV p24 antigen ELISA kit 2.0 (#0801002; ZeptoMetrix, Buffalo, NY, USA). SW 1990 and PANC-1 cells were infected with shISOC1 lentivirus or control virus at multiplicity of infection of 2 using polybrene (#H9268; Sigma-Aldrich; Merck KGaA). At 72 h after infection, green fluorescent protein (GFP) expression was observed and the achieved infection efficiency was 80%, and the expression of ISOC1 was analyzed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting, according to the subsequent protocols.

MTT assay

To test directly whether ISOC1 inhibition would affect cell viability and proliferation, an MTT assay was performed to compare the effects of decreased ISOC1 expression on cell numbers. SW 1990 and PANC-1 cells were transfected with shISOC1 lentivirus or control virus at a multiplicity of infection of 2 using polybrene. Stably-transfected cells were seeded into a 96-well plate (2×103 cells/well) at 37°C for 16 h, and after cell adhesion, 20 µl MTT (5 mg/ml; Genview, Houston, TX, USA; #JT343) was added and cultured at 37°C for 4 h. Subsequently, the media was completely removed and 100 µl dimethyl sulfoxide was added and optical density 490 was determined on a microplate reader. The viability of the cells was assessed by measuring the absorbance at 490 nm using a Microplate Absorbance Reader (Tecan Group, Ltd., Männedorf, Switzerland; #M2009PR). Each experiment was repeated three times.

Western blot analysis

Total protein was extracted from cell lines by incubating with 2X Lysis Buffer [100 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol and 2% mercaptoethanol] on ice for 10 min and sonication 5 sec each time for 4 times (200 W with 2 sec interval). Total protein was measured through the bicinchoninic acid method and separated by 10% SDS-PAGE. A total of 30 µg proteins were run on gels and transferred to polyvinyl difluoride membranes. The membranes were blocked in 5% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.; #37525) at room temperature for 1 hand then probed with the primary antibodies overnight at 4°C. The membranes were incubated with appropriate secondary antibodies (1:2,000 dilution), either peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG at room temperature for 1 h. GAPDH was used as a loading control. Subsequently, the antigen-antibody complexes were detected by using an enhanced chemiluminescent blotting analysis system.

RT-qPCR

Total RNA was extracted from cells using a SuperfecTRI, Total RNA Isolation reagent (Shanghai Pufei Biotechnology Co., Ltd., Shanghai, China; #3101-100). cDNA was transcribed from 1 µg total RNA using a Promega M-MLV kit (Promega Corporation, Madison, WI, USA; #M1705), according to the manufacturer's protocol. cDNA was used as the template for qPCR detection with primers and SYBR® Master Mixture on LightCycler480 (Roche Diagnostics, Basel, Switzerland). The primers for ISOC1 are forward, 5′-CGACATGCACCGCAAATTCG-3′, and reverse, 5′-TGAGCTGGATCTGCAACGG-3′. The primers for GAPDH are forward, 5′-TGACTTCAACAGCGACACCCA-3′, and reverse, 5′-CACCCTGTTGCTGTAGCCAAA-3′. The qPCR was performed with the following conditions: i) Hold at 95°C for 30 sec, ii) step-PCR for 40 cycles of 95°C for 5 sec and 60°C for 30 sec; and iii) dissociation at 95°C for 15 sec, 60°C for 30 sec and 95°C for 15 sec. The expression of the ISOC1 gene, and endogenous control gene GAPDH, was detected and analyzed. The relative mRNA expression level of ISOC1 in each sample was calculated using the comparative expression level 2∆∆Cq method (9). All experiments were conducted in triplicate for each data point.

ISOC1 mRNA level analysis from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) Portal

RNA sequencing results of pancreatic adenocarcinoma were downloaded from TCGA (http://www.cbioportal.org/datasets). RNA sequencing results of normal pancreas tissue were downloaded from GTEx (phs000424.v6.p1; ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs000424). ISOC1 sequencing results were extracted, normalized and integrated as transcripts per million.

Matrigel invasion assay

The Matrigel invasion assay was performed in a 24-well plate Transwell system (Corning Inc. Corning; NY, USA; #07-200-537). The Transwell inserts were coated with 100 µl Matrigel and incubated at 37°C for 30 min. A total of 5×103 SW 1990 cells were harvested and resuspended in 100 µl RPMI-1640 medium to the upper chamber of the Transwell system. The lower chamber was infused with 100 µl RPMI-1640 with 30% FBS. The Transwell system was incubated at 37°C for 20 h, and then the gel and cells in the upper chamber were cleared. Following 40% formalin fixation at room temperature for 15 min, the membrane was stained with Giemsa staining solution for 3–5 min at room temperature. Phase contrast images were captured and the cells on the lower side of the membrane were counted in 6 random visual fields under a ×20 objective lens of an inverted microscope (CKX41, Olympus Corporation, Tokyo, Japan).

Celigo counting assay

SW 1990 and PANC-1 cells were transfected with shISOC1 lentivirus or control virus at a multiplicity of infection of 2 using polybrene. A total of 15×102 cells/well were seeded in RPMI-1640 medium in a 96 well plate. The GFP-expressing cell number was counted with a Celigo image cytometer once a day at 37°C (Nexcelom Bioscience, Lawrence, MA, USA) for 5 days.

Annexin V assay

Apoptosis of SW 1990 cells was detected using an Annexin V-APC staining kit (eBioscience; Thermo Fisher Scientific, Inc.; #88-8007) after lentivirus infection at multiplicity of infection of 2 using polybrene for 6 and 8 days. Cells (5×105 cells/dish) were cultured at 37°C in 10-cm dishes to reach 80% confluency, and then they were harvested, washed twice with PBS and stained with 10 µl Annexin V-APC at 37°C for 10–15 min. Subsequently, cells were kept on ice in the dark and subjected to apoptosis analysis with a flow cytometer (EMD Millipore; #Guava easyCyte HT; Billerica, MA, USA). Data were analyzed with Guava Suite 3.3 software (EMD Millipore).

Caspase-Glo 3/7 Assay

SW 1990 and PANC-1 cells were transfected with shISOC1 lentivirus or control virus at a multiplicity of infection of 2 using polybrene. Caspase 3/7 activity in SW 1990 and PANC-1 cells following shCtrl or shISOC1 treatment was detected using a Caspase-Glo 3/7 kit (Promega Corporation). A total of 1×104 cells infected with shCtrl or shISOC1 were seeded in 96-well plates. After 3 days growth at 37°C, 100 ml Caspase 3/7 reagent were added to each well, mixed and incubated for 1 h at room temperature. Luminescence was measured using a M2000 Infinite Pro instrument (Tecan Group, Ltd.). Results of Caspase 3/7 activity were expressed as percentage of the negative control.

Migration assay

A total of 3×104 cells were seeded in 96 well plate and incubated at 37°C for 16 h to achieve 90% confluency. A 96 wounding replicator (VP scientific, Inc.; #VP408FH; San Diego, CA, USA) was used to scratch a monolayer across the surface of the well. Subsequently, the well was gently washed with RPMI-1640 medium to remove the detached cells. The cells were then incubated with fresh RPMI-1640 medium (containing 0.5% FBS) at 37°C for 24 h. Photos were captured at 0, 8 and 24 h. The wound area was analyzed and measured with Image J 1.51 software (National Institutes of Health, Bethesda, MD, USA).

Statistical analysis

Data are expressed as mean ± standard deviation from three independent experiments. The statistical analyses were performed using the GraphPad Prism (Version 6.0; GraphPad Software, Inc., La Jolla, CA, USA). Student's t-test was used for comparison between two groups. Two-way ANOVA with Bonferroni post-hoc test were used to compare the differences among multiple groups. P<0.05 was considered to indicate a statistically significant difference.

Results

ISOC1 is expressed in human pancreatic adenocarcinoma tissues and cell lines

The expression levels of ISOC1 mRNA in 179 pancreatic adenocarcinoma (PDAC) tissues and 4 normal pancreatic tissues were downloaded from TCGA database. The expression levels of ISOC1 mRNA from a further 171 normal pancreatic tissues were downloaded from the GTEx portal database. The mRNA expression levels of ISOC1 from PDAC and normal pancreatic tissues is plotted in the boxplot format in Fig. 1A. As depicted in Fig. 1A, the level of ISOC1 mRNA in PDAC tissues was significantly increased, compared with normal pancreatic tissues. Subsequently, the expression level of ISOC1 mRNA was assessed in the human PDAC cell lines, SW 1990, PANC-1 and AsPC-1, and in the normal cell line, HPED. RT-PCR analysis revealed that ISOC1 mRNA was expressed in all three human PDAC cell lines (Fig. 1B). Furthermore, the ISOC1 mRNA levels in PDAC cells were significantly increased, compared with normal cells (P<0.01). Therefore, elevated expression levels of ISOC1 may exert an important role in the pathogenesis of human PDAC.

Successful knockdown of ISOC1 in SW 1990 and PANC-1

To investigate the function of ISOC1 in pancreatic cancer, the expression of ISOC1 was inhibited by infection with shISOC1 in the SW 1990 and PANC-1 PDAC cell lines. The inhibition efficiency was confirmed by examining the mRNA level of ISOC1 using RT-qPCR, and the protein expression level of ISOC1 by western blotting, in shISOC1- and shCtrl-treated cell lines. The majority of the cells revealed GFPpositive expression, indicating a high infection efficiency. Furthermore, the mRNA levels of ISOC1 were significantly downregulated in shISOC1-treated cells, compared with the shCtrl group (Fig. 2A). Consistently, treatment with shISOC1 decreased the protein level of ISOC1 in the SW 1990 and PANC-1 cell lines (Fig. 2B). Collectively, these observations confirmed that ISOC1 silencing in SW 1990 and PANC-1 cell lines had been successfully accomplished.

Inhibition of cell proliferation by shISOC1

The potential effects of ISOC1 on cell proliferation were examined in SW 1990 and PANC-1 cells by Celigo cell counting and MTT assays. The same numbers of SW 1990 and PANC-1 cells (1,500 cells/well) from the shISCO1 and shCtrl groups were seeded into 96-well plates, and cell numbers were continuously counted using a Celigo plate reader over the course of the following 5 days. Cellular images and the cell number plots are depicted in Fig. 3A and B, respectively. The results indicated that SW 1990 and PANC-1 cells infected with shISOC1 presented a significantly reduced proliferative rate, compared with the control group (Fig. 3B and C). The MTT assay revealed similar results (Fig. 3D and E). During the 5 days of growth, the proliferation rates of the SW 1990 and PANC-1 cells were significantly inhibited by ISOC1 knockdown, compared with the control group. The aforementioned results revealed that ISOC1 may serve an important role in pancreatic cancer cell proliferation.

Knockdown of ISOC1 induces cell apoptosis

To determine the possible underlying mechanism of inhibition of cell proliferation, apoptosis was analyzed using Annexin V-staining flow cytometry and caspase3/7 assay. As depicted in Fig. 4A and B, the percentages of apoptotic cells in shISOC1-infected SW 1990 and PANC1 cells were significantly increased, compared with that in the shCtrl group. In agreement with the flow cytometry data, caspase 3/7 activity was significantly increased in shISOC1-infected cells, compared with that in the shCtrl group (Fig. 4C). These results indicated that knockdown of ISOC1 inhibited cell proliferation through induction of cell apoptosis.

Knockdown of ISOC1 impairs cell migration and invasion ability

In addition to the inhibition of cell proliferation by ISOC1 knockdown, the effects of cell migration (up to 24 h) and invasion (16 h) were also investigated in a shorter observational window, compared with the MTT assay (5 days). The same numbers of SW 1990 and PANC-1 cells (3×104) infected with shISOC1 and shCtrl were used for both assays. In the migration assay, significantly reduced migration rates were identified in the shISOC1 group, compared with the shCtrl group at 24 h (P<0.01; Fig. 5A and B). Consistently, significantly fewer cells invaded into the lower side of the chamber in the shISOC1 group, compared with the shCtrl group (Fig. 5C and D) after 16 h of incubation. Collectively, these results indicated that ISCO1 inhibition impaired the migration and invasive abilities of the pancreatic cells.

Discussion

In the present study, it was determined that the ISOC1 mRNA level is significantly increased in PDAC tissues, compared with normal pancreatic tissues, and the same trend was observed in PDAC cell lines, compared with normal pancreatic cells. Furthermore, the shISOC1-infected PDAC cell lines, SW 1990 and PANC-1, were demonstrated to have a reduced level of ISOC1 expression, compared with the respective control cell lines. Cell growth and proliferation was indicated to be significantly inhibited following ISOC1 knockdown. Furthermore, this inhibition of the cell growth and proliferation was determined to be associated with cell apoptosis. Finally, ISOC1 inhibition also resulted in an impairment of cell migration and invasion. To the best of our knowledge, this is the first study to have revealed how ISOC1 is involved in pancreatic cancer growth and migration.

Pancreatic cancer is notoriously difficult to detect early and to cure. Current therapeutic options for patients are limited and unsatisfactory (2). The observations of the present study demonstrated that ISOC1 may be a new potential intervention target in pancreatic cancer. Currently, it has not been established whether the effects of knockdown of ISOC1 on pancreatic cancer cells are dependent on, or otherwise associated with, the putative isochorismatase enzyme activity of ISOC1. Recently reported potential isochorismatase inhibitors, including suberoylanilide hydroxamic acid (10) and cinnamic acid (11), may help to address the previous question. Notably, ISOC2, an ISOC1 homolog, was determined to directly interact with the tumor suppressor p16INK4a, and to negatively regulate p16INK4a (12). Overexpressed ISOC2 inhibited the expression of p16INK4a. Our hypothesis is that ISOC1 may perform an action on p16INK4a similar to that of ISOC2, and that this may be the mechanism utilized by ISCO1 in terms of its role in tumor progression.

Previous studies revealed that ISOC1 was regulated by estrogen in the breast cancer cell line, MCF-7 (7,8). Furthermore, small interfering RNA knockdown of ISOC1 inhibits the growth of MCF-7 cells, which indicated that ISOC1 is involved in the growth of breast cancer cells (7). These results are consistent with those in the present study. This indicates that the positive regulation of ISOC1 on cancer cell proliferation may not be limited to pancreatic cancer and breast cancer, but may be a more widespread phenomenon in different types of cancer. It would be worthwhile to test the validity of this hypothesis. The previous study revealed that, in breast cancer, inhibition of ISOC1 results in a small decrease in the migration ability of the cells, although this difference was not observed to be significant (7). However, in the present study, it was determined that knockdown of ISOC1 did significantly decrease the migration and invasive ability of the pancreatic cancer cells. These different effects elicited by ISOC1 knockdown may be due to the different cancer context.

In conclusion, in the present study, the function of ISOC1 in pancreatic cancer was examined and it was determined that silencing ISOC1 expression induced apoptosis and suppressed cell proliferation in pancreatic cancer. These results indicated that ISOC1 could be a potential therapeutic target for the treatment of pancreatic cancer. However, further studies are required to fully elucidate the regulatory mechanisms of ISOC1 in pancreatic tumorigenesis.

Acknowledgements

Not applicable.

Funding

This study was supported by National Natural Science Foundation (grant no. 81300350) and by Science and Technology Commission Foundation of Shanghai Municipality (grant no. 16411950404).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

XW proposed the hypothesis and designed the study. LC performed the MTT and apoptosis assays, analyzed the data and wrote the article. YZ, MT and ZL performed the cell wound healing and Transwell assays, and analyzed the data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

American Cancer Society: Cancer Facts & Figures 2017. American Cancer Society. (Atlantla, GA). 2017.

2 

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med. 364:1817–1825. 2011. View Article : Google Scholar

3 

Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V: Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Walsh CT, Liu J, Rusnak F and Sakaitani M: Molecular studies on enzymes in chorismate metabolism and the enterobactin biosynthetic-pathway. Chem Rev. 90:1105–1129. 1990. View Article : Google Scholar

5 

Gronemeyer T, Wiese S, Ofman R, Bunse C, Pawlas M, Hayen H, Eisenacher M, Stephan C, Meyer HE, Waterham HR, et al: The proteome of human liver peroxisomes: Identification of five new peroxisomal constituents by a label-free quantitative proteomics survey. PLoS One. 8:e573952013. View Article : Google Scholar : PubMed/NCBI

6 

Pedersen CC, Refsgaard JC, Ostergaard O, Jensen LJ, Heegaard NH, Borregaard N and Cowland JB: Impact of microRNA-130a on the neutrophil proteome. BMC Immunol. 16:702015. View Article : Google Scholar : PubMed/NCBI

7 

Yamaga R, Ikeda K, Boele J, Horie-Inoue K, Takayama K, Urano T, Kaida K, Carninci P, Kawai J, Hayashizaki Y, et al: Systemic identification of estrogen-regulated genes in breast cancer cells through cap analysis of gene expression mapping. Biochem Biophys Res Commun. 447:531–536. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Rezaul K, Thumar JK, Lundgren DH, Eng JK, Claffey KP, Wilson L and Han DK: Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics. Genes Cancer. 1:251–271. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Fischer JJ, Michaelis S, Schrey AK, Diehl A, Graebner OY, Ungewiss J, Horzowski S, Glinski M, Kroll F, Dreger M and Koester H: SAHA capture compound-A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders. Proteomics. 11:4096–4104. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Hubrich F, Mordhorst S and Andexer JN: Cinnamic acid derivatives as inhibitors for chorismatases and isochorismatases. Bioorg Med Chem Lett. 23:1477–1481. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Huang XY, Shi ZC, Wang W, Bai J, Chen Z, Xu J, Zhang D and Fu S: Identification and characterization of a novel protein ISOC2 that interacts with p16(INK4a). Biochem Biophys Res Commun. 361:287–293. 2007. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May 2019
Volume 17 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cheng, L., Zhao, Y., Tang, M., Luo, Z., & Wang, X. (2019). Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro. Oncology Letters, 17, 4263-4270. https://doi.org/10.3892/ol.2019.10082
MLA
Cheng, L., Zhao, Y., Tang, M., Luo, Z., Wang, X."Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro". Oncology Letters 17.5 (2019): 4263-4270.
Chicago
Cheng, L., Zhao, Y., Tang, M., Luo, Z., Wang, X."Knockdown of ISOC1 suppresses cell proliferation in pancreatic cancer in vitro". Oncology Letters 17, no. 5 (2019): 4263-4270. https://doi.org/10.3892/ol.2019.10082